T45.0X4D

✓ Billable

Poisoning by antiallergic and antiemetic drugs, undetermined, subsequent encounter

Injury, poisoning and certain other consequences of external causes (S00-T88)

Check This Code

❌ Excludes1

inherited

Rules inherited from parent codes in the hierarchy.

  • poisoning by, adverse effect of and underdosing of phenothiazine-based neuroleptics (T43.3)

Clinical Description

ICD-10-CM code T45.0X4D represents poisoning by antiallergic and antiemetic drugs, undetermined, subsequent encounter. This code falls under the Injury, poisoning and certain other consequences of external causes (S00-T88) classification. It is a billable/specific code valid for HIPAA-covered transactions as of October 1, 2025 (FY2026). This code can be used to indicate a diagnosis for reimbursement purposes on insurance claims.

This is a 8-character code at the 7th level of specificity. This is the most specific code available in this subcategory. Coders should note that T45.0X4D has 1 Excludes1 restriction(s) — codes that cannot be reported together on the same claim.

Frequently Asked Questions

What is ICD-10 code T45.0X4D?

ICD-10-CM code T45.0X4D is "Poisoning by antiallergic and antiemetic drugs, undetermined, subsequent encounter". It belongs to the category: Injury, poisoning and certain other consequences of external causes (S00-T88).

Is T45.0X4D a billable ICD-10 code?

Yes, T45.0X4D is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.

What codes are excluded with T45.0X4D?

T45.0X4D has 1 Excludes1 rule(s). These codes are mutually exclusive and cannot be coded together on the same claim.

🧪 Validate Combinations

Add T45.0X4D to the Excludes Checker to validate against your full code list.

Open in Checker →

Code Information

CodeT45.0X4D
BillableYes
ParentT45.0X4
CategoryInjury, poisoning and certain other consequences of external causes (S00-T88)
Excludes11 rule(s)
Excludes20 note(s)

Data Source

CMS ICD-10-CM 2026 Tabular List

Updated October 1, 2025 (FY2026)